Site Editor

William J. Gradishar, MD, FACP, FASCO


William J. Gradishar, MD, on Maturing Data From the monarchE Trial: Expanding Role for CDK4/6 Inhibitors in High-Risk Hormone-Positive Breast Cancer

Posted: Wednesday, April 26, 2023

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the monarchE trial. When the study was first conducted, findings suggested there was a benefit to adding abemaciclib as a component of adjuvant therapy for patients with high-risk breast cancer. With longer follow-up, the data have become more compelling, Dr. Gradishar says, showing a sustained and expanded benefit to the use of this CDK4/6 inhibitor. He talks about how PARP inhibitors could be integrated into this treatment.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.